This stock is still not expensive despite its 343pc gain
Revenue rose by 19pc year on year, with organic growth (which excludes the impact of acquisitions) amounting to 11.1pc. Operating profit, meanwhile, was up 18.4pc on the prior year, with the company's operating profit margin relatively unchanged at roughly 9.8pc, as it was able to successfully raise prices in order to largely offset the effects of elevated inflation.
The company enjoyed strong performance from its electric vehicles and consumer electricals segments during the year, which more than compensated for a weak performance in its medical division that the company expects to only prove temporary in nature.
Its operations in North America posted strong growth. Sales in the region rose by 35pc year on year, so they now account for 46pc of total sales, thereby making it the company's largest geographical region. Although the US economy contracted at an annualised rate of 0.5pc in the first quarter of the year, it is widely expected to bounce back over the coming months – and with Voltex's flexible manufacturing footprint, it appears relatively well placed to overcome a prospective rise in US tariffs.
Clearly, history suggests that increased protectionism is extremely likely to have a negative impact on global economic growth. This could weigh on the company's financial performance in the short run and may lead to elevated share price volatility as investors pivot from cyclical stocks to defensives. However, a likely end to sticky inflation and the implementation of further interest rate cuts across developed economies mean the long-term outlook for the company's operating environment remains upbeat.
While the company's net debt rose by 14pc to around $175m (£129.5m) in the past year, it still has a relatively modest net gearing ratio of 47pc. Net interest costs, meanwhile, were covered nearly five times by operating profits in its latest financial year.
These figures suggest Volex has the financial means to not only overcome an uncertain near-term outlook for the world economy but also to engage in M&A activity. Indeed, the company stated in its results that it has an active acquisition pipeline.
Trading on a price-to-earnings ratio of 13.6, Volex appears to offer good value for money on a long-term view and scope for an upward rerating. Its relatively modest market valuation is, of course, somewhat surprising given not only its recent share price rise, but also because it has produced a 341pc capital gain since being added to our Aim portfolio in August 2018.
Over the same period, the FTSE Aim All-Share index has slumped by 30pc. This means the stock has outperformed the wider index by 371 percentage points in just under seven years.
In Questor's view, Volex continues to offer capital growth potential and scope for further index outperformance over the coming years. While its share price could prove to be relatively volatile in the near term due to an ongoing uncertain geopolitical environment, its solid balance sheet and sound competitive position mean it is well placed to benefit from an upbeat long-term economic outlook.
Questor says: buy
Ticker: VLX
Share price at close: 364.5
Update: Totally
While Volex has posted exceptionally high returns since being added to our Aim portfolio, another of our holdings, Totally, has recently gone into administration. The healthcare services provider's shares have subsequently been cancelled from trading on Aim.
Although Questor previously highlighted that it considered Totally to be at the higher end of the risk spectrum due to its relatively small size and uncertain operating environment, the news is still hugely disappointing.
Moreover, it reconfirms the importance of diversification – particularly among smaller companies. In many cases, they lack the breadth of operations of larger businesses that are typically better able to withstand tough operating conditions, periods of economic difficulty and, of course, unforeseen events.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
a day ago
- Daily Mail
Aussie share no-one has heard of POPS: Stock surges 72 times over - $14k instantly turns into $1m
An obscure rare earth miner's share price has skyrocketed from just four cents to $2.82 in a matter of hours. The 70-fold increase in the Kaili Resources share price occurred on Monday turning a modest $14,000 investment into a $1million windfall. The surge happened within just five-and-a-half hours from the start of trade, with the share price peaking at 3.30pm Sydney time, or just 30 minutes before the close of trade. But the Australian Securities and Investments Commission imposed a trading halt on Monday, that will continue until Wednesday, following a request from the company. 'Trading in securities in the entity will be temporarily paused pending a further announcement,' the ASX said. By then, profit takers had already sold, causing the price to more than halve back to $1.08 by the late afternoon. This was still the highest closing price since June 2002. Those who held on without profit selling still made a significant profit, with an initial $1,000 investment still worth $27,000. An obscure rare earth miner's share price has skyrocketed from just four cents to $2.82 in a matter of hours The surge from Friday's close at 3.6c started after Kaili Resources announced that afternoon that South Australia 's Department of Energy and Mining had given it approval to drill at three tenements in Lameroo, Karte and Coodalya in the Murray Basin. Kaili Resources, established in 1997, has languished under 80c for the last 20 years Kaili chairman Donghai Zhang and director Chunlin Liu are connected with the Chinese Yitai Group, which controls Inner Mongolia Yitai Coal Co.
Reuters
2 days ago
- Reuters
India's market regulator proposes allowing large firms to launch IPOs with smaller issue size
Aug 18 (Reuters) - India's market regulator on Monday proposed to reduce the minimum size of share sale for large companies looking to list their shares in a bid to simplify fund-raising. The proposal includes allowing companies to sell a minimum of 2.5% of their paid-up share capital in an initial public offering from the earlier mandated 5% if their market capitalisation was above 5 trillion rupees ($57 billion) after the listing. ($1 = 87.3590 Indian rupees)
Telegraph
5 days ago
- Telegraph
Rachel Reeves's inheritance tax raid has killed our portfolio. Here's our first step to salvaging it
Questor is The Telegraph's stock-picking column, helping you decode the markets and offering insights on where to invest. Inheritance tax relief on Aim shares was halved in last year's Budget. This means that, from April next year, the effective inheritance tax rate on qualifying Aim shares that have been held for at least two years will be 20pc instead of the current 0pc rate. Clearly, this could still represent a substantial tax saving in some cases. However, when coupled with the potential for further tax changes in future budgets, in Questor's view, it is no longer sufficiently appealing to justify the existence of our Aim portfolio. Indeed, by solely focusing on Aim shares, we have previously accepted the opportunity cost of missing out on high-quality companies that are listed elsewhere in the UK stock market in order to obtain a significant inheritance tax saving. Given that the inheritance tax saving from Aim shares could become even less enticing, this column feels that it is more logical to instead allow a broader range of companies to be held in the portfolio that can potentially deliver higher long-term returns. As a result, we will no longer consider just inheritance tax relief and will now include UK-listed companies from outside the FTSE 100 in our portfolio. The reason for excluding FTSE 100 stocks is twofold. Firstly, it limits the crossover with our wealth preserver and income portfolios, which are dominated by FTSE 100 stocks. Secondly, we wish to retain the portfolio's reliance on UK-focused firms because of our upbeat stance on the domestic economy's long-term prospects. Given that FTSE 100 members generate over 80pc of their revenue from abroad, versus 55pc for the FTSE 250, a portfolio that focuses on small and mid-cap stocks fits the bill. With that in mind, FTSE 250 member Cranswick becomes the first addition to our new-look portfolio. The food producer has been tipped several times by Questor over recent years, with its share price having risen by 71pc since our 'buy' recommendation in July 2022. In doing so, it has outperformed the FTSE 250 by 55pc. The company's recently released first-quarter trading statement showed that it continues to make encouraging progress. Like-for-like revenue rose by 7.9pc, with strong volume growth leading its top line higher. The company confirmed that it is on track to meet financial guidance for the full year, while its medium-term outlook remains upbeat. Indeed, the firm is expected to generate 7pc annualised earnings growth over the next two financial years. Some investors, of course, may feel that Cranswick's earnings multiple of 19.2 is a steep price to pay given its good, but not great, profit growth forecasts. Indeed, there are a wide range of small and mid-cap shares that offer superior earnings growth prospects over the coming years. However, in this column's view, the firm's relatively dependable financial performance as a result of its defensive characteristics means it represents good value for money. Furthermore, the company's solid financial position and substantial competitive advantage highlight its status as a high-quality business that is worthy of a premium valuation. For example, despite a 73pc rise in net debt during its latest financial year, the company's net gearing ratio amounts to just 18pc. Meanwhile, net interest costs were covered over 20 times by operating profits last year. Despite its modest use of leverage, return on equity stood at 14pc in the company's latest financial year. This suggests the firm has a clear competitive advantage, while a rise in its operating profit margin of 48 basis points to 7.6pc last year further indicates a continued improvement in the firm's competitive position. To make way for the addition of Cranswick, hospital software specialist Craneware will now be removed from the small and mid-cap portfolio. It has produced a 28pc capital gain since being added in January 2018. This represents a 57pc outperformance of the FTSE Aim All-Share index. In Questor's view, Cranswick offers a favourable long-term investment opportunity. Its solid fundamentals and upbeat, as well as relatively dependable, growth outlook mean it has scope to deliver further capital gains and index outperformance over the coming years. Ticker: CWK
